Bicalutamide in advanced prostate cancer. A review

Drugs and Aging

Volumn 12, Issue 5, 1998, Pages 401-422

  Goa, Karen L ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE;

ADVANCED CANCER; CASTRATION; CLINICAL TRIAL; CONTROLLED STUDY; DARK ADAPTATION; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; GYNECOMASTIA; HUMAN; INTERSTITIAL PNEUMONIA; LIBIDO; LIVER FUNCTION; MALE; MASTALGIA; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0031921272     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812050-00006     Document Type: Review

References (110)

1. Boring CT, Squires TS, Tong T, et al. Cancer statistics, 1994. CA-Cancer J Clin 1994 Jan/Feb; 44 (1): 7-26
2. Varenhorst E, Carlsson P, Pedersen K. Clinical and economic considerations in the treatment of prostate cancer. PharmacoEconomics 1994 Aug; 6: 127-41
3. Giovanucci E, Kantoff P, Spiegelman D, et al. The epidemic of prostate cancer and the medical literature: a causal association? Pros Cancer Pros Dis 1998; 1: 148-53
4. Schellhammer PF. Bicalutamide as an alternative for advanced PCa. Contemporary Urol 1996: 8 (12): 31-3
5. Soloway MS, Matzkin H. Antiandroizenic agents as monotherapy in advanced prostatic carcinoma. Cancer 1993 Feb 1; 71 Suppl.: 1083-8
6. Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodxnamics and mechanism of action. Urology 1996 Jan; 47 Suppl.: 13-25
7. Furr BJ, Valcaccia B, Curry B, et al. ICI 176,334: a novel nonsteroidal, peripherally selective antiandrogen. J Endocrinol 1987 Jun: 113: R7-9
8. 3H]cortisol binding to plasma proteins. J Steroid Biochem 1989; 33 (2): 251-5
9. Darbre PD, King RJH. Antiandrogen ICI 176,334 does not prevent development of androgen insensitivity in S115 mouse mammary tumour cells. J Steroid Biochem 1990 Aug 14; 36: 385-9
10. Berrevoets CA, Veldscholte J, Mulder E. Effects antiandrogens on transformation and transcription activation ot wild-type and mutated (LNCaP) andiogen receptors. J Steroid Biocheni Mol Biol 1993 Dec: 46: 731-6
11. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992 Mar; 41: 665-9
12. Fuhrmann U, Bengtson C, Reperithin G, et al. Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of cat expression by anti-androgens. J Steroid Biochem Mol Biol 1442 Sep; 42: 787-93
13. Furr BJA, Blackledge GP. Is there a place tor antiandrogen monotherapy? Excerpta Medica International Congress Series 1944; 1064: 157-75
14. Soloway MS, Schellhammer PF, Smith JA, et al. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology 1996 Jan; 47 Suppl. IA: 33-7
15. Mahler C, Van Cangh P, Bouffioux C, et al Endocrine effects of Casodex, a new non-sleroidal antiandrogen. Recent Advances in Urological Cancers Diagnosis and Treatment 1990 Jun 27-9, Paris: 42-45
16. Collinson MP, Tyrrell CJ, Wilkin TJ. The endocrine effects of tour doses of Casodex (ICI 176,334) in patients with prostatic carcinoma. Br J Cancer 1994 Jul; 70 Suppl. 22: 38. abstract no. P58
17. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-sleroidal anti-androgen Casodex in proslate cancer. Clin Endocrinol 1994 Oct: 41: 525-30
18. Chodak G, Sharifi R, Kasimis B, et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced proslate carcinoma. Urology 1995 Dec; 46: 849-55
19. Lee M. Ngan J, Ransone C, et al. Elevated serum testosterone levels during Casodex treatment: is it clinically significant? [abstract]. Ther Drug Monit 1993 Apr; 15: 137
20. Jones HB, Betton GR, Boudler AL, et al. Pathological and morphomctric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176.334) or bilateral orchidectomy. Urol Res 1944 Jul; 22: 191-5
21. Rulli SB, Gonzalez-Cahar SI, Campo S, et al. Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats. J Androl 1995 May-Jun, 16: 225-32
22. Chandolia RK, Weinbauer GF, Simoni M, et al. Comparative effects ot chronic administration of the non-steroidal antiandrogens flutamide and Casodex of the reproductive system of the adult male rat. Ada Endocrinol 1991 Nov: 125: 547-55
23. Mancher A, von Angerer E. Antiproliterative activity of casodex (ICI 176.334) in hormone-dependent tumours. J Cancer Res Clin Oncol 1993; 119: 669-74
24. Paris F, Weinbauer GF, Blum V, et al. The effect of androgens and antiandrogens on the immunohistochemical localisation of the androgen receptor in accessory reproductive organs of male rats. J Steroid Biochem Mol Biol 1994 Jan; 48: 129-37
25. Garnick MB. Hormonal therapy in the management ot prostate cancer: from Huggins to the present. Urology 1997 Mar: 49 Suppl. 3A: 5-15
26. Dearnaley DP. Cancer of the prostate. BMJ 1994 Mar 19; 308: 780-4
27. Teulsch G. Goubet F, Battmann T, et al. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 1994; 48 (1): 111-9
28. Mukherjce A, Kirkovsky L, Yao XT, et al. Enantioselective binding: of Casodex to the androgen receptor. Xenobiotica 1996 Feb; 26: 117-22
29. Luo S, Martel C, LeBlanc G, et al. Relative potencies of flutamide and Casodex: preclinical studies. Endocr Rel Cancer 1996; 3 (3): 229-41
30. Furr BJA. Relative potencies of flutamide and 'Casodex'. Endocr Rel Cancer 1997; 4(2): 197-202
31. Veldscholte J, Berrevocts CA, Brinkmann AO, et al. Antiandrogens and the mutated androgen receplorot LNCaPcells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992 Mar 3; 31: 2393-9
32. Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilisation. Urology 1996 Jul: 48: 157-63
33. Kuil CW, Mulder E. Mechanism of antiandrogen action: conformational changes of the receptor. Mol Cell Endocrinol 1994; 102: R1-5
34. Kuil CW, Berrevoets CA, Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 1996 Nov 17; 270 (46): 27569-76
35. Chandolia RK, Weinbauer GF, Nieschlag E. Effects of the non-steroidal antiandrogen Casodex on the pituitary-testicular axis on spermatogenesis in adult rats [abstract]. Acta Endocrinol 1991; 124 Suppl. 1: 35
36. Freeman SN, Mainwaring WIP, Furr BJA. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen. Casodex (ICI 176.334). Br J Cancer 1989 Nov; 60: 664-8
37. Bjerklund-Johansen TE, Majak M, Nesland JM. Testicular histology after treatment with the new antiandrogen Casodex for carcinoma of the prostate. A preliminary report. Scand J Urol Nephrol 1994 Mar; 28: 67-70
38. Luo S, Martel C, Chen C, et al. Daily dosing with flutamide or Casodex exerts maximal antiandrogen activity. Urology 1997 Dec: 50: 913-9
39. Eri LM, Urdal P. Effects of the nonsteroidal antiandrogen casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Eur Urol 1995; 27 (4): 274-9
40. Cockshott ID, Cooper KJ, Sweetmore DS, et al. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990; 18 Suppl. 3: 10-7
41. Bicalutamide prescribing information. Zeneca Pharmaceuticals. Wilmington, Delaware, USA, October 1995
42. McKillop D, Boyle GW, Cockshott ID, et al. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993 Nov; 23: 1241-53
43. Cockshott ID, Oliver SD, Young JJ, et al. The effect of food on the pharmacokinetics of the bicalutamide (Casodex) enantiomers. Biopharm Drug Dispos 1997; 18: 499-507
44. Furr BJA, Blackledge GRP, Cockshotl ID, Casodex: preclinical and clinical studies. In: Pasqualini JR, Katzenellenbogen BS, editors. Hormone dependent cancer. :, 1996: 397-424
45. Tyrrell CJ, Denis L, Newling D, et al. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. Eur Urol 1998; 33 (1): 39-53
46. Schellhammer PF, Block NL, Sharifi R, et al. Estimated potency of Casodex: a problematic design. Reply [letter]. Urology 1997 Aug: 50: 311-3
47. Cockshott ID, Plummer GF, Cooper KJ, et al. The pharmacokinetics of casodex in laboratory animals. Xenobiotica 1991 Oct; 21: 1347-55
48. Blackledge GRP, Cockshott ID, Furr BJA. Casodex(Rm) (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur Urol 1997 Feb; 31 Suppl. 2: 30-9
49. Cockshott ID, Sotaniemi EA, Cooper KJ, et al. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol 1993 Oct; 36: 339-43
50. Bicalutamide prescribing information. ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1996-1997, United Kingdom, p. 1278
51. Kaisary A, Klarskov P, McKillop D. Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide). Anticancer Drugs 1996 Jan; 7: 54-9
52. Kreis W, Kasimis B, Callahan-Squire M. Clinical trials with the nonsteroidal antiandrogen Casodex in the treatment of advanced prostate cancer [abstract no. 39]. Cancer Invest 1991; 9: 384
53. Newling DWW. The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase-II study of Casodex. Eur Urol 1990 Dec: 18 Suppl. 3: 18-21
54. Kotake T, Usami M. Isaka S, et al. Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer [in JAPANESE]. Hinyokika Kiyo 1966 Feb; 42: 157-68
55. Blackledge G, Kolvenbag G, Nash A. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anticancer Drugs 1946 Jan; 7: 27-34
56. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997 Sep; 50: 330-6
57. Soloway MS, Schellhammer P, Sharifi R, et al. A controlled trial of Casodex (hicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol 1996 Mar; 29 Suppl. 2: 105-9
58. Lunglmayr G. International Casodex Study Group. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. Anticancer Drugs 1995; 6: 508-13
59. Tyrrell CJ. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. Prostate 1992; 4: 97-104
60. Iversen P, Tveter K, Varenhorst E, et al. Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996 Apr; 30: 93-8
61. Kaisary AV, Tyrrell CJ, Bcacock C, et al. A randomised comparison of monotherapy with casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 1995; 28(3): 215-22
62. Bales GT, Chodak GW. A controlled trial of hicalutamide versus castration in patients with advanced prostate cancer. Urology 1996 Jan; 47 Suppl. IA: 38-43
63. Iversen P. Updale of monotherapy trials with the new antiandrogen. Casodex (IC1 176,334). Eur Urol 1994; 26 Suppl. 1: 5-9
64. Kasimis B, Chang V, Hwang S, et al. Long-term survival of patients with stage D2 prostate cancer treated with sequential bicalutamide 50mg followed by androgen deprivation (AD) or AD as initial therapy. Results of a randomized trial [abstract no. 1200]. Proceedings of ASCO 1997; 16: 336a
65. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients w ith previously untreated non-metaslatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51 (3): 389-96
66. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex'Tm (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 1998. In press
67. Boccardo F, Rubagotti A, Miglietta L, et al. Bicalutamide (B) monotherapy versus flutamide (F) plus goserelin (B) in prostate cancer (CA) patients (pts) [abstract no. 1128]. Proceedings of ASCO 1997; 16: 317a
68. Chatelain C, Fourcade RO, Delchamhre J. Bicalutamide (Casodex Rm) versus combined androgen blockade: open French multicentre study in patients with metastatic prostate cancer [abstract no. 1111]. Br J Urol 1997 Sep; 80 Suppl. 2: 283
69. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176.334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994; 26 Suppl. I: 10-4
70. Sinibaldi V, Carducci M, Abeloff M, et al. Experience with casodex in patients with stage D3 prostate cancer [abstract no. 1114]. Proceedings of ASCO 1997; 16: 313a
71. Kucuk O, Blumenstein B, Moinpour C, et al. Phase II trial of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: a Southwest Oncology Group (SWOG) Study (SWOG 9235) [abstract no. 618]. Proc Am Soc Clin Oncol 1996 Mar; 15: 245
72. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancel: the natural versus treated history of disease. J CIm Oncol 1997 Aug; 15: 2928-828
73. Joyce K, Fenton MA, Kode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonaf therapy. J Urol 1948 Jan; 159: 149-53
74. McCaffrey JA, Scher HI. 'Casodex': defining the role of antiandrogens. Cancer J Scientific Amer 1997; 3 (4): 204-8
75. Allwein J, Ekman P, Barry M, et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg symposium. Urology 1997 Apr; 49 Suppl.: 66-76
76. Fossa SD. Quality of life in advanced prostate cancer. Semin Oncol 1996 Dec: 23 Suppl 14: 32-4
77. Herr HW. Quality of life in prostate cancer patients. CA Cancer J Clin 1997 Jul-Aug; 47: 207-17
78. Albertsen PC, Aaronson NK, Müller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997 Feb; 49: 207-17
79. Borghede G, Karlsson J, Sullivan M. Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 1997 Oct; 158: 1477-86
80. Clean PD, Morrissey G, Osier O. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995 Jun: 4: 207-20
81. Iversen P, Tveter K, Varenhorst H, et al. Results of a Scandinavian multicenlre open phase III study of 'Casodex' versus orchidectomy in the treatment of metastatic prostatic carcinoma. Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment 1993; Paris. 17-19 Jun 1992: 120-5
82. Tammela T, Iversen P, Kaisary A, et al. A randomised comparison ol Casodex 150mg versvis castration in the treatment of advanced prostate cancer [abstract no. 993]. Eur Urol 1996; 30 Suppl. 2: 265
83. Schellhamnier PF, Venner P, Haas GP, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997 May; 157: 1731-5
84. Collinson MP, Daniel FN, Tyrrell CJ, et al. Response of carcinoma of the prostate to withdrawal of flutamide. Eur J Urol 1994; 72: 662-3
85. Kely WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993 Mar; 149: 607-9
86. Small HJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994 Mar; 43: 408-10
87. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995 Mar: 153 (Pt 2): 1070-3
88. Liebertz C, Kelly WK, Theodoulou M, et al. High dose Casodex lor prostate cancer: PSA declines in patients with flutamide withdrawal responses [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 232
89. Fenton MA, Rode P, Constantine M, et al. Bicalutamide for androgen-independent (AI) prostate cancer [abstract no. 684]. Proceedings of ASCO 1996 Mar 15; 15: 262
90. Kolvenbag GJCM, Blackledge GRP, Worldwide activity and safety of bicalutamide: a summary review. Urology 1996 Jan: 47 Suppl. IA: 70-9
91. Tyrrell CJ. Tolerability and quality of life aspects with the antiandrogen Casodex (ICI 176,334) as monotherapy lor prostate cancer. Eur Urol 1994; 26 Suppl. 1: 15-9
92. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalulamide. Urology 1997 Feb; 49: 283-4
93. Schellhammer PF. Fulminant hepatic failure associated with bicalutamide [letter]. Urology 1997; 50 (5): 827
94. Chodak GW. Bicalutamide-associated fulminant hepatic lailure [letter]. Urology 1997 Dec; 50: 1027
95. Palmberg C, Kylmala T, Tammela T. Reduction of flulamide-induced alanine aminotransferase elevation after replacement by hicalutaniide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Br J Urol 1997 May; 79: 808-9
96. Barradell LH, Faulds D. Cyproterone: a review of its pharma colony and therapeutic efficacy in prostate cancer. Drues Aging 1994; 5 (1); 59-80
97. Cox RL, Crawford FD. Estrogens in the treatment of prostate cancer. J Urol 1995 Dec; 154: 1991-8
98. Labrie F, Belanger A, Cusan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endocr Rel Cancer 1996; 3 (3): 243-78
99. Caubet J-F, Tosteson T, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71-8
100. Kirby RS. Is total androgen blockade now mandatory? Reviews on Endocrine Related Cancer 1993; 42: 31-43
101. Prostate panel: hormones overused, costly, unproven. Med Outcomes Guidelines Alert 1997 May 8; 5: 6-8
102. Denis L. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Prostate 1995 Nov: 27: 233-40
103. Eisenberger M, Crawford ED, McLeod D, et al. A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (PC) (NCI INT-0105 SWOG/ECOG) [abstract no. 3]. Proceedings of ASCO 1997; 16: 2a
104. Crawford ED. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer [letter]. Urology 1995 Dec; 46: 899
105. Zerbih M, Payan C. A controlled trial of bicalutamide versus flutamide, each in combination with leuteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer [letter]. Urology 1996 Oct; 48: 661-2
106. Labrie F, Simard J, Singh SM, et al. Estimated potency of Casodex: a problematic design [letter]. Urology 1997 Aug; 50: 309-11
107. Schellhammer P, Vogelzang N, Jones J, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Reply [letter]. Urology 1995 Dec; 46: 899-900
108. Akaza H, Isaka S, Usami M, et al. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Int J Urol 1996 Nov; 3: 468-71
109. Flutamide prescribing information. Mosby's Complete Drug Reference 1997 Physicians GenRx. pp. II-949-950
110. Blackledge GRP. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 1996 Jan; 47 Suppl. 1A: 44-7